ISIN IE00BYZK4776TER %0,40Assets 1.311 M €
Volatility 1y %16Worst fall 1y −%12Since 2016-09-08
Themes · general research
Genomics and biotech platforms
Sequencing, DNA synthesis, gene editing, AI drug discovery and diagnostics.
Can lose most
Can lose most of the money. Typical volatility %73, typical worst fall −%85; 3 of 7 companies are more than half below their high.
The weakest basket of the last four years (+1 %). Gene-editing names are 50–92 % below their highs, with binary clinical risk.
Typical volatilityMedian 1-year volatility of the theme's companies (annualised daily moves).
%73
Typical worst fallMedian of each company's worst peak-to-trough fall in five years (or since listing).
−%85
Typical distance from the high
−%50
Typical 1-year return
−%26
How to hold it in the EU
US-listed ETFs have no KID and cannot be bought by EU retail investors; these UCITS lines can. One fund line spreads the single-company risk.
ISIN IE00BYXG2H39TER %0,35Assets 1.016 M €
Volatility 1y %22Worst fall 1y −%7Since 2017-10-19
Green: available; dashed with “?”: the venue is offered, check the line in the terminal; crossed out: not available.
US theme ETFs (ARKG) are used only to measure the theme's risk: not buyable by EU retail.
The companies
Research data of 2026-10-15; where we score the company, its live Smart Score and red flags are shown.
| Ticker | Market cap | Revenue (y/y) | P/S | Volatility 1y | Worst fall | From high | 1 year | 12 m: ×2 / −50 % | Where | Our rating |
|---|---|---|---|---|---|---|---|---|---|---|
| ILMN Illumina: DNA sequencing | 41,0 B$ | 4,5 B$ (+%5) | 9× | %48 | −%83 | −%35 | +%186 | %5 / %3 | Freedom24IBKR | 8/10 |
| TEM Tempus AI: AI diagnostics | 12,3 B$ | 1,4 B$ (+%50) | 9× | %73 | −%60 | −%34 | −%28 | %4 / %0 | Freedom24IBKR | 1/10Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →+1 |
| CRSP CRISPR Therapeutics: gene editing (Casgevy) | 4,9 B$ | 13 M$ (−%65) | 363× | %58 | −%69 | −%50 | −%26 | %0 / %1 | Freedom24IBKR | 1/10Caution. Negative free cash flow in at least two of the last three years. More in the glossary →Caution. Share count growing 3–10 % a year over three years. More in the glossary → |
| TWST Twist: DNA synthesis | 9,3 B$ | 432 M$ (+%19) | 22× | %78 | −%92 | −%28 | +%392 | %27 / %18 | Freedom24IBKR | 1/10Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →+1 |
| BEAM Beam: base editing | 2,4 B$ | 156 M$ (+%159) | 15× | %72 | −%85 | −%76 | −%7 | %1 / %10 | Freedom24IBKR | 1/10Serious warning. Share count growing more than 10 % a year over three years. More in the glossary →Caution. Negative free cash flow in at least two of the last three years. More in the glossary →+1 |
| NTLA Intellia: in-vivo gene editing | 1,6 B$ | 60 M$ (+%13) | 27× | %98 | −%95 | −%92 | −%52 | %1 / %29 | Freedom24IBKR | 1/10Serious warning. Share count growing more than 10 % a year over three years. More in the glossary →Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →+1 |
| RXRX Recursion: AI drug discovery | 2,0 B$ | 55 M$ (−%15) | 37× | %74 | −%86 | −%82 | −%32 | %0 / %9 | Freedom24IBKR | 1/10Serious warning. Share count growing more than 10 % a year over three years. More in the glossary →Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary →+1 |
Survivorship: the list is of companies known in 2026; earlier names that went bankrupt or were taken private are missing, so the “×2” share is an upper bound.
The theme as a basket
Equal weights, monthly rebalance, 08.08.2022–14.10.2026, compared with the S&P 500.
| Equal-weight basket | CAGR | Volatility 1y | Worst fall | 1 year |
|---|---|---|---|---|
| CRSP NTLA BEAM RXRX TWST ILMN | %0 | %53 | −%59 | +%31 |
| S&P 500 (SPY) | +%15 | %16 | −%19 | +%13 |
The window starts near the 2022 low, which flatters every basket. Past results do not predict future ones.
Base rates: how such bets usually end
Research results to keep in mind before any upside.
IPOs, 3 years%38,5 of IPOs lost more than half in 3 years; %16,1 doubled, %0,5 grew 11× or more.
Jay Ritter, IPO statistics, Table 16e (9,195 IPOs 1975–2021), 23.03.2026
SPAC mergers−%51 average 1-year return after a SPAC merger (2012–2024).
Ritter / Gahng–Ritter–Zhang, Table 15c (625 de-SPACs 2012–2024), 05.10.2026
Thematic ETFs−%30 risk-adjusted over the first 5 years of specialised (thematic) ETFs.
Lottery stocks> %1 a month: how much “lottery” stocks (the biggest one-day jumps) underperform.
Where the gains come from%4 of US stocks created all the net wealth since 1926.
Volatility drag≈ %46 a year is lost to volatility at %96 volatility: +40 % a year on average compounds to about −6 %.
standard approximation: geometric mean ≈ arithmetic mean − σ²/2 (our arithmetic)
Quantum computingAI infrastructure and chipsNuclear power and small reactorsSpaceRobotics and autonomyCrypto equities and bitcoin products
Source: Nasdaq historical closes 15.10.2021–14.10.2026; stockanalysis.com fundamentals 15.10.2026; justETF profiles and quotes 15.10.2026 · Research data of 2026-10-15 · Methodology and sources
Buradan sözleşmeden çıkın · AB tüketicileri: Bir satın alma işlemini iptal etmek için 14 gün.